Boehringer Ingelheim

Yuhan makes $325M cancer bet to challenge Boehringer, Takeda
Yuhan makes $325M cancer bet to challenge Boehringer, Takeda
Fierce Pharma
Yuhan
cancer
Boehringer Ingelheim
Takeda
HER2 inhbitor
non-small cell lung cancer
Flag link:
Zealand, Boehringer's drug meets main weight-loss goal in mid-stage trial
Zealand, Boehringer's drug meets main weight-loss goal in mid-stage trial
BioSpace
Boehringer Ingelheim
Zealand Pharma
obesity
clinical trials
BI 456906
Flag link:
Boehringer Ingelheim to Mine Ginkgo’s Molecules in $406M Undruggable Targets Deal
Boehringer Ingelheim to Mine Ginkgo’s Molecules in $406M Undruggable Targets Deal
BioSpace
Boehringer Ingelheim
Ginko Bioworks
bioactive molecules
Flag link:
Boehringer Ingelheim to surf with Melbourne-based biotech in $181M neuropsychiatric therapy deal
Boehringer Ingelheim to surf with Melbourne-based biotech in $181M neuropsychiatric therapy deal
Fierce Biotech
Boehringer Ingelheim
Kinoxis Therapeutics
neuropsychiatric
Flag link:
Boehringer Ingelheim breaks ground on €285M API plant in Germany
Boehringer Ingelheim breaks ground on €285M API plant in Germany
Fierce Pharma
Boehringer Ingelheim
drug manufacturing
Germany
Flag link:
Boehringer Ingelheim opens new biotechnology R&D center in Germany
Boehringer Ingelheim opens new biotechnology R&D center in Germany
Pharmaceutical Business Review
Boehringer Ingelheim
Germany
R&D
Flag link:
Playing catch-up, Boehringer taps RetinAI for AI boost to eye disease R&D
Playing catch-up, Boehringer taps RetinAI for AI boost to eye disease R&D
Fierce Biotech
Boehringer Ingelheim
RetinAI
artificial intelligence
geographic atrophy
R&D
Flag link:
Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more
Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more
CP Wire
CVS Health
Signify Health
M&A
Ferring Pharmaceuticals
Pfizer
Bristol Myers Squibb
Eli Lilly
Novo Nordisk
Boehringer Ingelheim
Jardiance
Ozempic
drug pricing
Eliquis
CMS
Flag link:
Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more
CVS Health
Signify Health
M&A
Ferring Pharmaceuticals
Pfizer
Bristol Myers Squibb
Eli Lilly
Novo Nordisk
Boehringer Ingelheim
Jardiance
Ozempic
drug pricing
Eliquis
CMS
Flag link:
Boehringer signals intent in obesity
Boehringer signals intent in obesity
EP Vantage
Boehringer Ingelheim
Zealand Pharma
obesity
clinical trials
BI 456906
Flag link:
Boehringer Ingelheim and Eli Lilly's Jardiance gets big lift from heart failure indications
Boehringer Ingelheim and Eli Lilly's Jardiance gets big lift from heart failure indications
Fierce Pharma
Boehringer Ingelheim
Eli Lilly
Jardiance
heart failure
Flag link:
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
Marketscreener
Covant Therapeutics
drug discovery
R&D
Boehringer Ingelheim
cancer
ADAR1
Flag link:
Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report
Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report
Fierce Pharma
Medicare
drug pricing
Merck
Novo Nordisk
Eli Lilly
Boehringer Ingelheim
JNJ
Flag link:
Spotlight – Cystic fibrosis developers take a deep breath
Spotlight – Cystic fibrosis developers take a deep breath
EP Vantage
cystic fibrosis
MRNA
Vertex Pharmaceuticals
4D Molecular Therapeutics
Arcturus Therapeutics
Arrowhead Pharmaceuticals
Boehringer Ingelheim
Eloxx Pharmaceuticals
Krystal Biotech
Moderna Therapeutics
Oxford BioMedica
ReCode Therapeutics
SpliSense
Sumitomo Pharmaceuticals
Tessera Therapeutics
Flag link:
New Report Reveals Pharmaceutical Industry Social Media Pioneers
New Report Reveals Pharmaceutical Industry Social Media Pioneers
LBB Online
Ogilvy Health
social media
Bristol Myers Squibb
Boehringer Ingelheim
Roche
Flag link:
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
Flag link:
Roche, Boehringer tap biosensor firms for patient studies
Roche, Boehringer tap biosensor firms for patient studies
Pharmaphorum
Roche
Boehringer Ingelheim
patient monitoring
biosensors
clinical trials
Sysnav Healthcare
Strados Labs
Flag link:
Boehringer, Takeda make it into global top 15 employer list
Boehringer, Takeda make it into global top 15 employer list
Pharmaphorum
Boehringer Ingelheim
Takeda
Top Employers
Flag link:
Sanofi expects Zantac arbitration case with Boehringer Ingelheim to be resolved early this year
Sanofi expects Zantac arbitration case with Boehringer Ingelheim to be resolved early this year
Endpoints
Sanofi
Boehringer Ingelheim
Zantac
legal
Flag link:
Boehringer Ingelheim deepens its collaboration with Click Therapeutics in a deal worth $460M
Boehringer Ingelheim deepens its collaboration with Click Therapeutics in a deal worth $460M
Endpoints
Boehringer Ingelheim
Click Therapeutics
digital therapeutics
schizophrenia
Flag link:

Pages